December #168 : Vital Insights From Vienna - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

The POZ 100

The POZ 100: 1 to 10

The POZ 100: 11 to 20

The POZ 100: 21 to 30

The POZ 100: 31 to 40

The POZ 100: 41 to 50

The POZ 100: 51 to 60

The POZ 100: 61 to 70

The POZ 100: 71 to 80

The POZ 100: 81 to 90

The POZ 100: 91 to 100




Stress Test

Vital Insights From Vienna

Treatment Twofer

HIV Testing Sooner

Worry Wart

Spice It Up




Blood, Sweat and Tears

Positive Rewards

Pop Projects

Party Favors

Men in Love

Hot Dates

Pozarazzi




Editor's Letter

Letters

Healing Touch

GMHC Treatment Issues- December 2010



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

December 2010


Vital Insights From Vienna

by Tim Horn

This past July, experts in the fields of HIV/AIDS science, policy and activism, as well as HIV-positive people, journalists, government officials, religious leaders and the staffs of AIDS service organizations gathered in Vienna for the XVIII International AIDS Conference.

POZ and AIDSmeds were there, covering everything from breaking treatment and advocacy news to the latest reports on vaccines, new drugs in the development pipeline, microbicides, criminalization and condoms. Log on to poz.com/aids2010 for our extensive coverage. In the meantime, we’ve compiled some HIV treatment and prevention highlights from this year’s confab:
 

When to Start? Current HIV treatment recommendations—start when CD4s fall below 500—are on the mark in terms of reducing the risk of AIDS or death, according to results from the CASCADE cohort study. No benefit was seen among those starting with 500 or more CD4s over the three-year study period, though it is possible a benefit may become apparent over a longer period of time.

Spare Me. Two novel regimens showed promise in Vienna: Reyataz plus Isentress (without Norvir or nukes) and Kaletra plus Isentress (without nukes). While not yet ready for prime time, both regimens are proving comparable with standard combos. Isentress resistance is of concern, however.  

Dueling Nukes. Epzicom appears to work just as well as Truvada as components of first-line therapy, according to a Canadian study. These findings challenge earlier trials suggesting that Truvada trumps Epzicom in patients with high pre-treatment viral loads.

New Drug News. ViiV’s integrase inhibitor S/GSK-572 is performing well in a first-time treatment study and shows potential for some people with Isentress-resistant HIV. Tibotec’s non-nuke rilpivirine had similar efficacy and fewer side effects than Sustiva in two clinical trials, though the potential for HIV resistance to non-nuke Intelence is worrisome. And making its data debut was Boehringer Ingelheim’s Viramune XR—an extended release, once-daily version of the non-nuke.

Treatment as Prevention. A vaginal microbicide containing the nuke tenofovir cut HIV infection rates by 39 percent in a clinical trial of nearly 900 South African women. Among those who used the gel correctly at least 80 percent of the time they had intercourse, HIV transmission rates were slashed 54 percent. Watch for studies using a two-drug gel—tenofovir and emtricitabine—and similar microbicides for anal use.                      

Search: Vienna, XVII International AIDS Conference, treatment, prevention, nukes, drugs, advocacy, vaccine


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    Reginaldb06
    Dallas
    Texas


    Heartland4now
    Tacoma
    Washington


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.